BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Day In Review: EPIX Pharmaceuticals (EPIX) Buys Predix Pharmaceuticals For $90 Million


4/4/2006 5:48:48 PM

April 3, 2006 – Epix Pharma will buy Predix Pharma, a privately held biotech that attempted to make its IPO last October; the FDA approved initial human testing of new cancer drug from CancerVax; Inhibitex sank 66% after Veronate failed a Phase III trial; Cortex put the clinical trials of CX717 on hold; Incyte abandoned an HIV drug after it caused too many side effects; GlaxoSmithKline put an early end to a Phase III trial of its breast cancer drug because of strongly positive data; GlaxoSmithKline also entered a partnership with Sirna to develop RNA interference drugs; ImClone received European approval of an add-on indication for Erbitux; CombinatoRx identified a number of different drug combinations effective against brain cancer; Advanced Cell Technology licensed somatic cell reprogramming IP from TranXenoGen; Pharmacopeia inlicensed anti-hypertensive compounds from Bristol-Myers Squibb; a mouse equivalent of Tarvacin from Peregrine was effective against two forms of cancer; and Geron will pit its lead anti-cancer drug candidate against solid tumor malignancies. The Centient Biotech 200™ closed 29 points lower at 3937.67, a loss of .73%. More details...

Read at ChinaBio Today

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES